In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Cardioprotective effect of angiotensin converting enzyme inhibitors and beta-blockers in the primary prevention of cardiotoxicity: systematic review and meta-analysis of randomised studies

Session Poster session 1

Speaker Sergio Moral

Congress : EuroEcho 2019

  • Topic : imaging
  • Sub-topic : Imaging: Myocardial Disease
  • Session type : Poster Session
  • FP Number : P367

Authors : S Moral (Girona,ES), N Coma (Girona,ES), A Eraso (Girona,ES), E Ballesteros (Barcelona,ES), G Vinas (Girona,ES), JM Frigola (Girona,ES), M Morales (Girona,ES), R Robles (Girona,ES), X Albert (Girona,ES), P Fluvia (Girona,ES), A Fort (Girona,ES), P Vilardell (Girona,ES), I Romera Martinez (Girona,ES), R Brugada (Girona,ES)

S Moral1 , N Coma1 , A Eraso2 , E Ballesteros3 , G Vinas2 , JM Frigola1 , M Morales1 , R Robles1 , X Albert1 , P Fluvia1 , A Fort1 , P Vilardell1 , I Romera Martinez2 , R Brugada1 , 1University Hospital de Girona Dr. Josep Trueta - Girona - Spain , 2Institut català d'oncologia - Girona - Spain , 3Centre d'Atenció Primaria Pare Claret, ICS., Radiology Department - Barcelona - Spain ,

On behalf: none



Chemotherapy cardiotoxicity is a serious complication in breast and haematological malignancies.  However, its primary prevention with angiotensin converting enzyme inhibitors (ACEI)/angiotensin II receptor antagonists (ARB) and/or beta-blockers (BB) medication has discrepant results. The aim of our study was to establish whether primary prevention using these treatments prevents cardiotoxicity and whether any of them is superior to the others.


A systematic review and meta-analysis was performed following a search of EMBASE, MEDLINE and PsycINFO from January 2005 to April 2019 of all randomised studies evaluating primary prevention of cardiotoxicity by chemotherapy with any of these treatments. Cardiotoxicity was defined as the drop of the left ventricular ejection fraction below 50% or greater than 10% and/or clinical heart failure during the first year of follow-up.


Nine randomised studies with 913 participants in which chemotherapy was performed were included: 337 (37%) received BB, 152 (17%) received ACEI/ARB, 45 (5%) received BB+ACEI and 379 (41%) were controls. One hundred and eight cases (12%) developed cardiotoxicity (follow-up range: 1-12 months). Patients receiving cardioprotective treatment had a lower risk of developing cardiotoxicity than controls (RR=0.381, IC95%, 0.160-0.911, P=0.030, I2=63.2%; Fig.1). The subgroup analysis showed a non-significant tendency for both treatments to have a cardioprotective effect (BB: RR=0.477; IC95%, 0.178-1.275; P=0.140; I2=57.3%) / ACEI/ARB: RR=0.283; IC95%, 0.027-2.982; P=0.293; I2=79.0%). There was no difference between both treatments in those studies comparing them (RR=0.743, CI95%, 0.325-1.698, P=0.481, I2=0.0%). The estimated number of patients to be treated to avoid one case of cardiotoxicity was 10 patients.


Primary prevention with BB and/or ACEI/ARB reduces cardiotoxicity by chemotherapy during the first year in breast and haematological malignancies.  For every 10 patients treated, one case of cardiotoxicity could be avoided.

Figure 1. Cases treated with BB and/or ACEI/ARB versus control group without treatment of the different randomised studies comparing the number of patients who developed cardiotoxicity during the first year.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are